Amylin Pharmaceuticals Announces Appointment of Daniel M. Bradbury as Chief Executive Officer Effective March 1, 2007
January 30 2007 - 4:05PM
PR Newswire (US)
SAN DIEGO, Jan. 30 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (NASDAQ:AMLN) today announced that Daniel M.
Bradbury will become President and Chief Executive Officer on March
1, 2007. He will succeed Ginger L. Graham, who has led the company
since 2003. "I've had the pleasure of working with Dan for more
than eleven years, first as a board member and then as a member of
the management team. Dan has a deep appreciation for the two
critical elements required to build a sustainable biopharmaceutical
company: the value of scientific innovation and the importance of
building capabilities to deliver those innovations to patients,"
said Graham. "I look forward to Dan's leadership and am excited to
return to a role as a board member in support of Dan and the future
success of Amylin." "We are entering an exciting phase at Amylin,"
said Bradbury. "BYETTA and SYMLIN are well-positioned to drive the
company's near-term growth, and the long-acting formulation of
BYETTA in development provides tremendous mid-term opportunity.
Longer-term, our integrated neurohormonal approach to therapies for
obesity has great potential to impact this worldwide epidemic and
provide a foundation for future sustainable growth. We have a
tremendous opportunity to challenge science and change the lives of
millions of people by bringing new medicines to those who need
them." "Ginger's leadership has been instrumental in the company's
transition from a research and development entity to a fully
commercialized biopharmaceutical leader," commented Joseph C. Cook,
Jr., Chairman of the Board. "We thank her for her tireless efforts
and look forward to her continued contributions as a member of the
Board of Directors. In addition, we look forward with confidence to
working with Dan as Amylin continues its journey to improve the
lives of people with diabetes and obesity. The passion and
commitment of the Amylin senior leadership team and all the Amylin
team members are key to executing our plans and delivering results
that enable us to drive value through innovation." In June 2006,
Mr. Bradbury, 45, was named President and COO and became a member
of the Board of Directors. He previously served as Executive Vice
President from June 2000 until his promotion to COO in June 2003.
He joined Amylin in 1994 and has held officer-level positions in
Corporate Development and Marketing during that time. Prior to
joining Amylin, Mr. Bradbury spent ten years at SmithKline Beecham
Pharmaceuticals, where he held a number of sales and marketing
positions. He is a member of the board of directors of Illumina,
Inc. and Novacea, Inc. He also serves as a board member for BIOCOM
and the Keck Graduate Institute's Board of Trustees. Mr. Bradbury
is a member of the Royal Pharmaceutical Society of Great Britain
and serves on the UCSD Rady School of Management's Advisory
Council. He received a Bachelor of Pharmacy from Nottingham
University and a Diploma in Management Studies from Harrow and
Ealing Colleges of Higher Education. About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company committed to
improving lives through the discovery, development and
commercialization of innovative medicines. Amylin has developed and
gained approval for two first- in-class medicines for diabetes,
SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide)
injection. Amylin's research and development activities leverage
the company's expertise in metabolism to develop potential
therapies to treat diabetes and obesity. Amylin is located in San
Diego, California with over 1500 employees nationwide. Further
information on Amylin Pharmaceuticals is available at
http://www.amylin.com/. This press release contains forward-looking
statements about Amylin, which involve risks and uncertainties. The
Company's actual results could differ materially from those
discussed herein due to a number of risks and uncertainties,
including risks that BYETTA or SYMLIN may be affected by
competition, unexpected new data, technical issues, or
manufacturing and supply issues; risks that our clinical trials
will not be completed when planned or may not replicate previous
results; risks and uncertainties that Amylin will be able to
complete manufacturing scale-up and construction and validation of
its manufacturing facility on a timely basis, or at all; risks that
the FDA may not approve the Company's sNDAs or product candidates;
and other risks inherent in the drug development and
commercialization process. Commercial and government reimbursement
and pricing decisions and the pace of market acceptance may also
affect the potential for BYETTA or SYMLIN. These and additional
risks and uncertainties are described more fully in the Company's
recently filed Form 10-Q. Amylin disclaims any obligation to update
these forward-looking statements. DATASOURCE: Amylin
Pharmaceuticals, Inc. CONTACT: Alice Bahner, Executive Director,
Investor Relations of Amylin Pharmaceuticals, Inc., +1-858-552-2200
Web site: http://www.amylin.com/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024